Skip to content

Savara SVRA Software and Technology Licenses, Net

Software and Technology Licenses, Net at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
Innoviva, Inc. logo
Innoviva, Inc.INVA
Theravance Biopharma logo
Theravance BiopharmaTBPH
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
TRV
Trevi Therapeutics, Inc.TRVI

Other financials

Income statement

See full
Revenue-
Operating income-$39.0M-37.1%
Net income-$37.3M-40.0%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$38.8M+98.4%
Total debt$30.1M+1.8%
Total equity$176.0M+19.1%
Total assets$221.6M+17.1%

Cash flow

See full
Operating cash flow-$33.0M-21.5%
CapEx$54.0K+1,700%
Free cash flow-$33.1M-21.7%

Valuation

See full
Market cap$1.19B+134%
Enterprise value$1.19B+127%
P/S4,648.7×

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Return on equity-80%+4.7pp
Debt / equity0.2×0.0×
Current ratio13.5×-1.4×

Where this comes from

Reported directly by Savara in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Savara’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Savara's software and technology licenses, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Savara's software and technology licenses, net?
Savara (SVRA) reported software and technology licenses, net of $886K in Q1 2026.
How has Savara's software and technology licenses, net changed year-over-year?
Savara's software and technology licenses, net decreased by 11.5% year-over-year, from $1M to $886K.
What is the long-term trend for Savara's software and technology licenses, net?
Over 5 years (2020 to 2025), Savara's software and technology licenses, net has grown at a -19.6% compound annual growth rate (CAGR), from $250K to $84K.